Search - tctmd.com

Displaying 1 - 20 of 101

Sort: Relevancy | Date

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

Year in Review: Top Prevention Stories of 2025

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

Remission From Prediabetes Halves CV Risk: Registry Data

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

July 21, 2025

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

News Daily News

Weight-Loss Drug MariTide Gains Momentum in Phase II Trial

June 25, 2025

Amylin Analogue Boosts Weight Loss When Added to GLP-1

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

June 24, 2025

Medicaid Patients with Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

News Daily News

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

April 17, 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

News Daily News ACC 2025

STRIDE: GLP-1 Boosts Walking Capacity in Diabetic PAD Patients

March 29, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

October 23, 2024

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

News Daily News

Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows

September 25, 2024

Semaglutide May Ease Tobacco Use, Study Suggests

News Daily News

Semaglutide May Ease Tobacco Use, Study Suggests

August 01, 2024

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

News Daily News

Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea

Michael O'Riordan

June 21, 2024

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

News Daily News

No Signs of Hypoglycemia Causing CVD in CAROLINA and CARMELINA

Michael O'Riordan

January 05, 2024

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.